XWPharma
PrivateLast Round
Series C
Sep 17, 2020
Total Funding Raised
$63M
Company Overview
XWPharma operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series C round in September 2020.
XWPharma is a biotechnology company that develops innovative therapeutics to address sleep, neuropsychological, and other neglected central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
XWPharma Comparables
Compare XWPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CuraSen Therapeutics, Inc. | 77% | |
| Alkermes plc | 75% | |
| Sage Therapeutics | 74% |
For institutional investors. Book with your work email.
XWPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 17, 2020 | ||||
| Series B | Sep 20, 2017 | ||||
| Series A | Sep 1, 2014 |
For institutional investors. Book with your work email.
XWPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kleiner Perkins China | Series A |
| WI Harper Group | Series C, Series B |
| Orient Hontai Capital | Series C |
| KTB Ventures | Series B, Series C |
| SANY Group | Series C |
| Daol Investment | Series B, Series C |
| Kleiner Perkins | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Grew 37% QoQ, from 19 to 26 employees.
- Apr 18, 2026
Grew 35% QoQ, from 17 to 23 employees.
For institutional investors. Book with your work email.
XWPharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about XWPharma's valuation, stock price, and market status.
Is XWPharma a public or private company?
XWPharma is a private company.
What is the current stock price of XWPharma?
XWPharma is a private company, so its shares have no public market price. Caplight tracks XWPharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is XWPharma worth (valuation)?
Valuation information for XWPharma is not publicly available.
Can I buy XWPharma stock?
XWPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was XWPharma's last funding round?
XWPharma's most recent funding round was Series C on September 17, 2020.
Who are the main investors in XWPharma?
Key investors in XWPharma include Kleiner Perkins China, WI Harper Group, Panacea Venture Healthcare.
Will XWPharma IPO soon?
No public IPO plans have been announced for XWPharma.
How can I track XWPharma secondary market activity?
Caplight tracks bids, offers, and trades in XWPharma's shares on secondary markets.